Last $1.30 USD
Change Today -0.0001 / -0.01%
Volume 59.5K
BIOD On Other Exchanges
Symbol
Exchange
BIOD is not on other exchanges.
As of 2:43 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

biodel inc (BIOD) Snapshot

Open
$1.25
Previous Close
$1.30
Day High
$1.32
Day Low
$1.25
52 Week High
03/6/14 - $3.71
52 Week Low
10/14/14 - $1.20
Market Cap
29.5M
Average Volume 10 Days
84.1K
EPS TTM
$-0.60
Shares Outstanding
22.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODEL INC (BIOD)

Related News

No related news articles were found.

biodel inc (BIOD) Related Businessweek News

No Related Businessweek News Found

biodel inc (BIOD) Details

Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. It is involved in developing proprietary insulin formulations for type 1 and type 2 diabetes patients; ultra-rapid-acting insulin analog-based formulations; glucagon formulations and presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia or very low concentrations of blood glucose; and other recombinant human insulin-based formulations. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

35 Employees
Last Reported Date: 12/20/13
Founded in 2003

biodel inc (BIOD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $677.9K
Chief Medical Officer
Total Annual Compensation: $427.3K
Compensation as of Fiscal Year 2013.

biodel inc (BIOD) Key Developments

Biodel Inc. to Report Q4, 2014 Results on Dec 17, 2014

Biodel Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Dec 17, 2014

Biodel Inc., Q4 2014 Earnings Call, Dec 17, 2014

Biodel Inc., Q4 2014 Earnings Call, Dec 17, 2014

Biodel Inc. Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program

Biodel Inc. announced that the company has initiated enrollment of normal human subjects in a Phase 1 clinical trial of its lyophilized glucagon formulation designed for use in a proprietary auto-reconstitution device intended for the rescue of patients with severe hypoglycemia. The combination of the formulation and the auto-reconstitution device constitutes the Glucagon Emergency Management (GEM) system, which is intended to be a more user-friendly glucagon presentation compared to emergency kits currently marketed by Eli Lilly and Novo Nordisk. The Phase 1 proof of concept study is a 6-arm cross over trial in 12 healthy volunteers in which the pharmacokinetics, pharmacodynamics, and safety of 1 mg doses of the GEM glucagon formulation, administered subcutaneously and intramuscularly, will be compared to similar injections of both marketed glucagon products. These data will be help finalize the design and select the comparator to be used in the pivotal bioequivalence study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOD:US $1.30 USD -0.0001

BIOD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOD.
View Industry Companies
 

Industry Analysis

BIOD

Industry Average

Valuation BIOD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODEL INC, please visit www.biodel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.